Pasithea Therapeutics Corp. (KTTA) Press Releases https://ir.pasithea.com/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/pasithea/files/theme/images/logo-sm.png Pasithea Therapeutics Corp. Logo Equisolve Investor Relations Suite <![CDATA[Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity]]> https://ir.pasithea.com/news-events/press-releases/detail/138/pasithea-therapeutics-announces-grant-of-fast-track Wed, 01 Apr 26 07:01:00 -0400 https://ir.pasithea.com/news-events/press-releases/detail/138/pasithea-therapeutics-announces-grant-of-fast-track <![CDATA[Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference]]> https://ir.pasithea.com/news-events/press-releases/detail/137/pasithea-therapeutics-to-present-at-the-oppenheimer-36th Tue, 17 Feb 26 07:01:00 -0500 https://ir.pasithea.com/news-events/press-releases/detail/137/pasithea-therapeutics-to-present-at-the-oppenheimer-36th <![CDATA[Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines]]> https://ir.pasithea.com/news-events/press-releases/detail/136/pasithea-therapeutics-provides-outlook-on-pas-004-clinical Tue, 13 Jan 26 07:01:00 -0500 https://ir.pasithea.com/news-events/press-releases/detail/136/pasithea-therapeutics-provides-outlook-on-pas-004-clinical <![CDATA[Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock]]> https://ir.pasithea.com/news-events/press-releases/detail/135/pasithea-therapeuticsannounces-closing-of-60-million Tue, 02 Dec 25 07:00:00 -0500 https://ir.pasithea.com/news-events/press-releases/detail/135/pasithea-therapeuticsannounces-closing-of-60-million <![CDATA[Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock]]> https://ir.pasithea.com/news-events/press-releases/detail/134/pasithea-therapeuticsannounces-pricing-of-60-million Fri, 28 Nov 25 09:20:00 -0500 https://ir.pasithea.com/news-events/press-releases/detail/134/pasithea-therapeuticsannounces-pricing-of-60-million <![CDATA[Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS]]> https://ir.pasithea.com/news-events/press-releases/detail/133/pasithea-therapeutics-announces-1-million-award-by-als Tue, 25 Nov 25 07:00:00 -0500 https://ir.pasithea.com/news-events/press-releases/detail/133/pasithea-therapeutics-announces-1-million-award-by-als <![CDATA[Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data]]> https://ir.pasithea.com/news-events/press-releases/detail/132/pasithea-therapeutics-announces-completion-of-cohort-7-in Mon, 24 Nov 25 07:00:00 -0500 https://ir.pasithea.com/news-events/press-releases/detail/132/pasithea-therapeutics-announces-completion-of-cohort-7-in <![CDATA[Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients]]> https://ir.pasithea.com/news-events/press-releases/detail/131/pasithea-therapeutics-announces-positive-pas-004-tablet Fri, 21 Nov 25 12:35:00 -0500 https://ir.pasithea.com/news-events/press-releases/detail/131/pasithea-therapeutics-announces-positive-pas-004-tablet <![CDATA[Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study]]> https://ir.pasithea.com/news-events/press-releases/detail/130/pasithea-therapeutics-announces-positive-phase-1-data Thu, 20 Nov 25 16:01:00 -0500 https://ir.pasithea.com/news-events/press-releases/detail/130/pasithea-therapeutics-announces-positive-phase-1-data <![CDATA[Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients]]> https://ir.pasithea.com/news-events/press-releases/detail/129/pasithea-therapeutics-announces-activation-of-clinical Tue, 04 Nov 25 07:03:00 -0500 https://ir.pasithea.com/news-events/press-releases/detail/129/pasithea-therapeutics-announces-activation-of-clinical